IMPROVING ONCOLOGY EXPLORATION WITH BUILT-IN KRAS ASSAY PROVIDERS AND RAS ASSAYS

during the rapidly evolving field of oncology study, exact and effective mutation screening is very important for producing specific therapies. The KRAS companies Platform plays a pivotal part Within this landscape by offering complete options for KRAS mutation profiling and Investigation. KRAS mutations, found in about 95% of RAS-similar oncogenic